Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody drug shows promise in early cancer trial

NCT ID NCT06929195

First seen Apr 17, 2026 · Last updated May 22, 2026 · Updated 2 times

Summary

This early-phase trial tested a new drug called TQB2210 in 16 people with advanced cancers that had stopped responding to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on some cancer cells, aiming to block signals that help tumors grow. The main goals were to find a safe dose and see if the drug could shrink tumors, especially in stomach or gastroesophageal junction cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOURS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

    Changsha, Hunan, 410005, China

  • Shanghai Tenth Hospital, Tongji University

    Shanghai, Shanghai Municipality, 200032, China

  • The Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032, China

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510000, China

Conditions

Explore the condition pages connected to this study.